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The mRNA distribution m the brain and the coupling to cellular effector systems of four somatostatin receptors (SSTR14) was studied. All four 
SRIF receptor subtypes were expressed in cortex and htppocampus. In addition. SSTRl mRNA was relatively abundant in the spinal cord whereas 
SSTRZ mRNA was also present m the striatum. The SSTR3 gene was predominantly expressed m the olfactory bulb and in the cerebellum. 
Conflicting results about the effector coupling of SSTRl-3 have been published prevtously. We have stably expressed human SSTRl4 in HEK 
293 human embryonal kidney cells. Agomst binding to the receptor subtypes, including the recently cloned SSTR4, inhibited the formatton of 
forskolin-Induced CAMP. Is is concluded that, in an approprtate cellular environment. all four receptor subtypes can functionally couple to the 
Inhibition of adenylyl cyclase. 
SRIF receptor; Brain; Adenylyl cyclase: CAMP; G-protein 
1. INTRODUCTION 
Somatostatin (somatotropin release inhibiting factor, 
SRIF) is an important regulator of endocrine and exo- 
crine secretion. It acts on many different cell types by 
inhibiting the secretion of hormones including growth 
hormone (GH), insulin, glucagon, gastrin, and secretin 
[l-3]. In addition, SRIF was shown to act as a neuro- 
transmitter [4-61 and to display neurotrophic properties 
on sympathetic, dorsal root ganglion and motor neu- 
rons [7,8]. 
The regulatory effects of SRIF are mediated by high- 
affinity membrane receptors on the target tissues which 
are coupled to GTP-binding proteins (G-proteins) [9- 
12]. Pretreatment of SRIF receptor positive cells with 
pertussis toxin (PTX) abolished their ability to interact 
with cellular effector systems like the adenylyl cyclase 
system indicating the involvement of PTX-sensitive G- 
proteins [13.14]. 
We have recently used an expression-cloning strategy 
to isolate a complementary DNA (cDNA) encoding a 
rat somatostatin receptor [15]. Based on the distribution 
of the cloned receptor and on the excellent correlation 
between the ability to displace radioligand binding from 
receptors expressed in COS-1 cells and their inhibitory 
activity on GH release from pituitary cells, we con- 
cluded that we had cloned the cDNA for the SRIF 
receptor type responsible for the inhibition of growth 
hormone release from the pituitary cells. 
Two other groups have independently isolated SRIF 
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receptor genomic and cDNA clones based on their se- 
quence similarity with monoaminergic receptors [ 16 
181. SRIF receptors contain seven putative membrane 
spanning regions and display sequence and structural 
homology to the family of G-protein coupled receptors, 
in particular to the monoaminergic receptors. 
A total of five SRIF receptor subtypes [19-241 and 
one splice variant of our rat clone [25] have recently 
been cloned from various species. This process was 
greatly facilitated by the absence of introns in the cod- 
ing regions of the receptor genes and by the extremely 
high sequence conservation between the SRIF receptor 
subtypes. 
While various nomenclatures have been introduced 
by different authors. the one proposed by Bell and Re- 
isine [26] seems most widely accepted and is used in this 
report with the exception that SSTR4, based on the 
submission date, refers to the clones isolated by Bruno 
et al. [20] and Rohrer et al. [24] and SSTRS to the clone 
described by O’Carroll et al. [22]. 
Here, we describe the distribution of the mRNAs 
encoding receptors SSTRl, 2, 3 and 4 in the brain. In 
addition, we demonstrate that all four receptor subtypes 
inhibit the formation of CAMP when stably expressed 
in HEK 293 human embryonal kidney cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Culture media and serum were obtained from Gibco BRL The 
somatostatin analogues Octreottde (SMS 201-995, Sandostatin). Tyr’- 
Octreotide (SDZ 204090) and SRIF-14 were synthetized at Sandoz 
Pharma (Basle, Swttzerland) All other chemicals were obtained from 
commercial sources. Iodinatton of Tyr’-Octreottde and Tyr”-SRIF-14 
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was performed by the chloramine-T method as described [27]. Ol- 
igonucleottdes were synthesized on a 380A Applied Biosystems syn- 
thesizer. 
2.2. RN.4 isolation and Northern hlot an&m 
Total cellular RNAs were purified from frozen tissues by the guani- 
dmium thiocyanate/ acid phenol method [28]. Poly(A1’ RNA was 
enriched by two passages over an ohgo(dT1 cellulose column as de- 
scribed [29]. For Northern blot analysts, the RNAs were fractionated 
on a 1 o/c agarose gel containing 2.2 M formaldehyde and transferred 
to Hybond N membranes (Amersham) by pressure blotting After UV 
crosshnkmg the RNAs were hybridized to “P-1abelled smgle stranded 
DNA probes generated by an asymmetric PCR (mSSTR1. 2. 3) or to 
a riboprobe (mSSTR4). 
Plasmids clones for the mouse SSTRl, 2 and 3 genes were kindly 
provided by Dr. Graeme I. Bell, Chicago [16,23]. For the generation 
of smgle stranded DNA probes anti-sense primers corresponding to 
sequences located between the putative transmembrane regions IV 
and V of the SSTRs were designed. The primer sequences were 
CCGTGCCATCGCTGTTGGCT (mSSTR1). TCCTGCCCCACT- 
GGTTGCTC (mSSTR2) and GCATGTGGCAGGTGCTCATG 
(mSSTR3). After lmeartzatton of the clones mSSTR1. 2 and 3 with 
&I, MmeI and Ncol. respecttvely. 30 cycles of “P-1abelled run-off 
replications were performed as described [30] to generate single- 
stranded anti-sense DNA. 
To synthesize a mouse SSTR4 receptor hybridization probe from 
the correspondmg region of this receptor, a fragment of the mouse 
SSTR4 gene was amplified by PCR. Primer sequences (TGTCAAC- 
CATGTGTCCCTCA and TAATACGACTCACTATAGGGAGC- 
AGGCAGGTTCTGCTTGCA) were designed based on the pub- 
lished rat SSTR4 sequence [20]. The second ohgonucleottde had as 
5’-addition the T7 promotor sequence (21 base pairs) The PCR reac- 
tion (50~1) contained 10 mmol/l Trts-HCl. pH 8.3. 1.5 mmol/l MgCl?. 
50 mmol/l KC]. 0.1 mg/ml gelatm, 0.2 mmol/l dNTPs. lOpmo1 of each 
primer, 1OOng of mouse genomic DNA and 2.5 units Tuq polymerase. 
34 PCR cycles were performed using a PREMllI (LEP Scientific) 
thermocycler (1 min 94°C. 30 s 63OC. 30 s 72°C) A fragment of the 
expected size (280 bp) was obtained, gel purified (Qiaex, Dtagen) and 
cycle-sequenced (Promega TaqTrack sequencing kit). The amphfica- 
tion product displayed highest sequence homology to the rat SSTR4 
gene (data not shown) and was less homologous to the other SSTR 
subtypes. A [“PI-1abelled riboprobe was synthetized from the amph- 
fied mSSTR4 gene fragment by in vitro transcription with T7 RNA 
polymerase. The probe hybridized to two RNAs of the expected size 
for rat SSTR4 mRNAs (2.4 and 6.0 kb; [20]), thus ensurmg that we 
had amplified a portion of the mouse SSTR4 gene. 
Hybridization was performed at 55°C (DNA probes) or 65°C (ribo- 
probes) in 0 5 M NaHPO, pH 7.2, 7% (w/v) SDS. 1 mM EDTA. 50% 
(v/v) formamtde [31] for 16 to 24 h. The membranes were washed twice 
at room temperature in 2 x SSC, 0.1% SDS for 15 mm and twice for 
30 min in 0.1 x SSC, 0.1% SDS at 65-75°C. Kodak X-OMAT AR 
films were exposed to the blots at -80°C with intensifying screens for 
2 to 6 days. Before subsequent hybridizations the probes were re- 
moved by washing the filters with boilmg 0.1% (w/v) SDS. 
2.3. In sttu hybridizution 
The ohgonucleotides specific for SSTRl (GCCTCCAGACTCCA- 
GATTCTCGGGCTGGAAGTCGTCCACG, [16]), SSTRZ (CGCG- 
TTGCTTGTCATGTCGTAGTATGGCTCTGTCTGGTTG, [ 151) 
SSTR3 (TTCTTCATCCTCCTCCTCTTCAGTCTTCTCTGGAG- 
GTCCC, [23]) and SSTR4 (GCAGCGGATTGCCGTGGAGAGC- 
AGCCGAACGCTGAACCAA and GCAATGGAGGGCATATG- 
CATCCTGGGCCACCTCTGCTTTT, [20]) were labelled at their 3’ 
ends with terminal desoxynucleotidyltransferase (TdT, Boehringer, 
Mannhetm) and [“P]dATP (3,000 Ci/mmol, Amersham). The labelling 
reactions were carried out by incubating 2 pmol of ohgonucleottde for 
2 h at 37°C m a 30 ~1 volume containing 16 pmol of labelled dATP 
and 25 units of TdT m 100 mM sodium cacodylate. pH 7.2, 2 mM 
CoCl,, and 0.2 mM dithiothreitol (DTT). The probes were purified by 
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chromatography through a NACS PREPAC column (BRL) accord- 
mg to the manufacturer’s mstructions. 
Cryostat sections (lo-20 pm) were au-dried. fixed for 20 min at 
room temperature m a freshly prepared solution contammg 4% (w/v) 
paraformaldehyde m PBS (2.6 mM KC], 1 4 mM KHZP04. 136 mM 
NaCl. 8 mM Na,HPO,) The slides were then washed once in 3 x PBS, 
twice in 1 x PBS. for 5 mm each and incubated in a freshly prepared 
solution of predigested pronase at a final concentration of 24 U/ml m 
50 mM Trts-HCl. pH 7.5, 5 mM EDTA for 10 min. The proteolytic 
activity was stopped by a 30 s immersion m 1 x PBS containing 2 
mg/ml glycine. The shdes were rinsed twice m PBS for 2 min each. and 
dehydrated for 2 mm each tn a graded series of ethanol (60%. 80%. 
95%, 100%). Tissue sections were dried at room temperature. 
The probe was diluted to a final concentration of l-2 x 10’ cpm/ml 
in buffer containing 50% formamide. 600 mM NaCl. 10 mM Trts-HCI. 
pH 7.5, 1 mM EDTA, 1 x Denhardt’s solution (0.02% Ftcoll, 0.02% 
polyvinylpyrrohdone, 0.02% BSA), 500 pg/ml yeast tRNA and 10% 
dextran sulfate Each section was covered with 60~1 of the hybridtza- 
tion solution and a Nescofilm coverslip was placed on top to prevent 
evaporation. The slides were placed m humid boxes and Incubated at 
37°C for 17 h. Followmg hybrtdtzatton, the coverslips were removed 
by flotation in a solution contammg 600 mM NaCl. 30 mM Tris-HCl, 
pH 7.5. and 1 mM EDTA. The slides were subsequently washed at 
60°C for 4 h in the same buffer (with 4 changes). Then the tissues were 
dehydrated by tmmersion in 70% and 95% ethanol containmg 0.3 M 
ammomum acetate pH 7.0. 2 mm each and air dried. Hybridization 
signal were detected by autoradtography on /I-max film (Amersham, 
UK). Exposure time ranged from 6 h for the SSTR3 oligonucleottdes 
to 12 days for the other oligos. Sections were stamed with 1% Cresyl 
violet m order to identify brain structures according to Pavinos and 
Watson [32]. 
HEK 293 human embryonal kidney cells (Amertcan Type Culture 
Collection) were grown in mmtmal essential medium (MEM, Gibco, 
No 04llOlO90) supplemented with 10% (v/v) fetal calf serum and 2 
mM L-Glutamm For transfected cell lmes 500 pug/ml G418 (active 
drug: Gibco BRL) was added to the medium. 
2.5. Expression qf humun SSTR subtypes In HEK 293 cells 
Four human SRIF receptor subtypes, SSTRl-4 were stably ex- 
pressed in HEK 293 human embryonal kidney cells, Clones for the 
human SSTRs 1, 2 and 3 were kindly provided by Dr. Graeme I. Bell. 
Chicago [ 16.191 The SSTR coding sequences were subcloned into the 
vector pcDNAI (Invitrogen) containmg the cytomegalovirus (CMV) 
promotor The human SSTR4 coding region cloned mto a similar 
CMV-based expression vector (pCMX) was kindly provided by Dr. 
R. Schdle, Sandoz. Basle 20 pg of the constructs for hSSTR2.3 and 
4 were cotransfected with 1 fig pMClneo polyA (Stratagene) as de- 
scribed [33] Cells expressing hSSTR2, 3 and 4 could be obtained by 
thts cotransfection method. We failed to generate SSTRl-expressing 
cells using this procedure. Therefore. a 3.3 kb ScaI fragment of 
pcDNA1 contammg the CMV promotor sequence together with the 
hSSTR1 coding sequence and the polyadenylation signal was inserted 
into the HincII site of pOG45 (Stratagene). a vector contammg a 
neomycin gene cassette on the same unit. Usmg this construct we 
readily obtained cell clones expressing high levels of hSSTR1. 
The selection with the neomycin analog G418 (500 &ml) was 
started after 72 h and continued for three weeks. Individual cell clones 
were isolated, propagated and tested for specific binding of radiola- 
belled SRIF-14. For each receptor subtype three individual cell clones 
which revealed specific, high-affinity [“51]Tyr”-SRIF-14 binding, 
were selected for further analyses. 
2.6. Receptor bindmg a;rsays 
SRIF receptor assays were performed as described previously [15]. 
HEK 293 cells stably expressing SSTR subtypes l-4 were grown to 
confluency in 24 well plates. For receptor binding studies. cells were 
washed twice with 10 mM HEPES, pH 7 6, contaming 5 mM MgCl?, 
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20 &ml bacitracin and 0.5% (w/v) bovine serum albumin The cells 
were incubated with 30.000 cpm of either [‘251]Tyr”-SRIF-14 or 
[“51]Tyr’-SMS 201-995 (specific activity 2,000 Wmmol) in 300 ,~l 
HEPES buffer for one hour at room temperature. The incubation was 
terminated by washing the cells twice with cold HEPES buffer. Cells 
were detached with 10% (w/v) SDS and the radioactivity bound to the 
cells was determined in an LKB gamma counter (80% counting effi- 
ctency). Non-specific binding of the radioligand was defined as bind- 
ing in the presence of either 1 ,uM SRIF-14 or SMS 201-995. Compe- 
tition binding experiments were performed by mcubatmg the cells with 
increasing concentrations of unlabelled SRIF-14. Binding curves were 
generated from triplicate determmations using the computer fitting 
programme of De Lean [34]. 
2.1. Adenylyl q&se assq 
Cells grown to confluency in 24-well plates were labelled with 
[‘Hladenine (2 ,UJ/ml) for 4 h in the presence or absence of pertussis 
toxin (100 ng/ml, Sigma). The cells were then washed twice in HEPES- 
buffered salt solution (HBS; 130 mM NaCl, 5.4 mM KCI. 1.8 mM 
Car& 0.8 mM MgSO,. 0.9 mM NaH,PO,, 25 mM glucose, 20 mM 
HEPES, pH 7.4) and incubated in the same buffer supplemented with 
1 mM isobutyl-methylxanthine (IBMX). Adenylyl cyclase was stimu- 
lated with 3 ,uM forskolin in the presence of dtfferent concentrations 
of SRIF-14 or SMS 201-995. After 15 min of incubation. cells were 
extracted with 5% trichloracetic acid. [-‘H]ATP and [‘HIcAMP were 
separated by sequential chromatography on Dowex and Alumina 
columns as described [35]. Data are plotted as cAMP/ATP ratios 
normalized to the response obtained with forskolin alone (100%). 
3. RESULTS 
3.1. Brain distribution of SRIF receptor mRNAs 
The mRNA distribution in the brain of somatostatin 
receptor subtypes SSTR14 was studied by Northern 
blotting and in situ hybridization (Fig. 1; Fig. 2). For 
Northern blot analyses on mouse tissues receptor spe- 
cific probes were generated. Under high stringency con- 
ditions, these probes hybridized to single RNAs of dif- 
ferent size for each receptor subtype indicating the 
absence of cross hybridization (Fig. 1). All four receptor 
subtypes are expressed in hippocampus and cortex. We 
also detected SSTRl mRNA in spinal cord and substan- 
tia nigra. In addition to hippocampus and cortex, 
SSTR2 mRNA was present in spinal cord, substantia 
nigra, and striatum. SSTR3 mRNA was relatively 
abundant in the olfactory bulb and in the cerebellum. 
The SSTR4 probe hybridized to two rat mRNAs of 
about 2.4 and 6.0 kb (not shown), but on mouse RNAs 
it hybridized only to a single mRNA species of about 
6.0 kb (Fig. 1). SSTR4 mRNA was present at rather low 
levels throughout the mouse brain but could be readily 
detected in hippocampus and cortex (Fig. 1). We have 
not yet investigated the nature of the two SSTR4 
mRNA species present in rat tissues. A splice variant of 
the SSTR2 RNA has been decribed which is also signif- 
icantly more abundant in rat than in mouse tissues [25]. 
SSTR2 receptor probes label two bands in blots with rat 
RNAs [15] but only one band in blots with mouse 
RNAs (Fig. 1). 
In situ hybridization on rat mesencephalon sections 
revealed a distribution of SSTR subtype mRNAs in the 
rat brain which was in agreement with the Northern 
SSTRl 
SSTRZ - 2.4 
SSTR3 - 4.3 v 
* 
SSTR4 - 6.0 
GAPDH - 1.5 
Fig. 1. RNA blot analysis of SSTR 14 gene expression in the mouse 
brain. Per lane 15 pg total RNAs prepared from tissues of 60-day-old 
BALB/c mice were loaded and hybridtzed to “P-labelled receptor 
subtype specific probes, Three blots were prepared using the same 
RNA preparation. After the SSTRl hybridization the filter was 
stripped and rehybridtred with the SSTRJ probe. To compare the 
amounts of RNA all filters were subsequently rehybridtzed with a 
probe for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH. 
[48]). An example for a GAPDH hybridization is shown (4 h expo- 
sure). Sizes of hybridizmg RNAs are given in kb. 
blot analysis on mouse brain tissues (Fig. 2). The ol- 
igonucleotides specific for the four SRIF receptor sub- 
types hybridized to different layers of the cerebral cor- 
tex. The highest densities of SSTR- 1 signals were found 
in layers V-VI of the cerebral cortex, in the granular 
layer of the dentate gyrus, and in the amygdala (Fig. 
2a). Signals for SSTR2 were found in the frontal cere- 
bral cortex (layers IV, V and VI), in the CA1 area of the 
hippocampus, in the central grey, in the granular cell 
layer of the dentate gyrus and in the amygdala (Fig. 2b). 
High levels of SSTR3 hybridization were found in the 
amygdala, in the granular layer of the dentate gyrus and 
in the red nucleus (Fig. 2~). The highest densities of 
SSTR4 mRNAs were found in the pyramidal layer and 
the CA1 area of the hippocampus (Fig. 2d). 
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Fig. 2. Drstribution of SSTRI (a), SSTRZ (b). SSTR3 (c) and SSTR4 (d) hybndtzation stgnals in mesencephalon sections of adult rat brain m sttu 
Dark areas indicate Intense hybridization. Abbreviations: CAI, CA2. CA3. fields CAl. 2. and 3 of Ammon’s horn. respectively: CC: central grey: 
DC: dentate gyrus; PMCo: posteromedial cortical amygdalotd nucleus; RMC: red nucleus magnocellular: SuCo. supertor colhculus: S. Subiculum, 
SNc: substantia nigra, compact 
3.2. Expression of SRIF receptor subtE’pes in HEK 293 
cells 
Human somatostatin receptor subtypes (hSSTRl-4) 
were stably expressed in HEK 293 human embryonal 
kidney cells. To determine the binding properties of 
SRIF analogs to SSTR l-4, competition binding-experi- 
ments were performed using [“51]Tyr”-SRIF-14 as 
specific radioligand. [“51]Tyr”-SRIF-14 exhibited high- 
affinity binding to all four receptor subtypes. Represen- 
tative competition curves are shown in Fig. 3. The 
C specific binding of [“51]Tyr”-SRIF-14 was displaced 
by SRIF- 14 in a monophasic manner which is charac- 
teristic for binding to a single class of receptors. 
C The inhibitory concentrations for half maximal 
C inhibition (IC,,) were calculated to be 3.6 2 
0.8 x lo-” M, 2.2 & 0.4 x lo-” M. 3.5 + 0.9 x IO-” M 
and 1.5 f 0.2 x 10m9 M. (n = 3-6) for SSTR 1-4, 
respectively. As expected from previous studies 
the SRIF analogue SMS 201-995 displayed high- 
affinity binding only to cells expressing SSTR2 
[ 15,23,24,36]. 
Very low specific binding of both [1’SI]Tyr”-SRIF-14 
and [‘251]Tyr3-SMS 201-995 could be determined on 
untransfected HEK 293 cells, consistent with the obser- 
vation that 293 cells naturally express low levels of 
SSTR2 receptors [37]. However, this binding comprised 
less than 5 percent of the total [“51]Tyr”-SRIF-14 bind- 
ing to the transfected cell lines. 
3.3. Second messenger couphg oj‘ SRIF receptors 
The ability of SRIF-14 and SMS 201-995 to interfere 
with the forskolin-stimulated rise in CAMP levels was 
studied in intact HEK 293 cells expressing human 
SSTR1-4. A concentration of forskolin was chosen (3 
,DM) which allows to detect both the stimulation and the 
inhibition of adenylyl cyclase [38]. In HEK 293 cells 
stably transfected with hSSTR1. 2. 3, or 4, forskolin 
stimulated cellular CAMP levels to more than ten times 
the basal levels. The CAMP formation was inhibited by 
SRIF- 14 in a dose-dependent manner (Fig. 4). The max- 
imal SRIF-14 mediated inhibition of CAMP formation 
was at least 70% for all four receptor subtypes. The 
somatostatin analog SMS 201-995. which displays high 
affinity for SSTR2 and a moderate affinity to SSTR3 
[23,36] but low affinity for SSTRl and SSTR4 [16,24]. 
also inhibited the forskolin-induced CAMP formation in 
cells expressing SSTR2 and SSTR3 as expected. 
Occasionally. SRIF-14 and SMS 201-995 slightly in- 
hibited the forskolin-induced CAMP formation in un- 
transfected HEK 293 cells to about 10 percent of the 
maximal response. This indicates that the strong inhibi- 
tion of the CAMP formation seen in the transfected cells 
is mediated through the SRIF receptor subtypes overex- 
pressed in the HEK 293 cells. The slight effect of nano- 
molar concentrations of SMS 201-995 in cells express- 
ing SSTRl and 4 may be related to the low SSTR2 
background in these cells (Fig. 4). 
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Fig. 3. Expression of SRIF receptor subtypes in HEK 293 cells Concentration dependence for the inhibition of ‘%Ty$‘-SRIF-14 binding by 
unlabelied SRIF-14. Results are expressed as percentage of maximal specific binding in the absence of competitor. The non-specific bmding was 
less than 20% of the total binding. 
Pretreatment of the cells with pertussis toxin abol- 
ished the ability of the activated receptors to inhibit 
CAMP formation indicating that all four receptors in- 
hibit adenylyl cyclase activity via pertussis toxin-sensi- 
tive G-proteins (Fig. 4). 
4. DISCUSSION 
The four somatostatin receptor subtypes SSTRl-4 
studied are expressed in an overlapping, but distinct 
distribution in the rodent brain. The distribution of 
SSTRl-4 mRNAs as studied by Northern blot analysis 
and in situ hybridization is generally consistent with 
that of SRIF binding sites determined in autoradiogra- 
phic studies C39-413. A major exception was observed 
for the cerebellum. SRIF receptors are believed to be 
not expressed in the adult cerebellum but are transiently 
expressed during development ]41-43]. However, 
SSTR3 mRNA was relatively abundant in adult cere- 
bellum (Fig. I). This apparent discrepancy between oc- 
curence of SSTR3 mRNA and receptor protein ex- 
pressed in the cerebellum requires further analysis. 
At present, it is difficult to correlate specific SRIF 
functions with the different receptor subtypes. Our pre- 
vious conclusions that inhibition of GH release is medi- 
ated by the SSTR2 receptor type fl5] is consistent with 
the characteristics of this receptor described here. In 
addition to its effects on the inhibition of hormone re- 
lease SRIF acts as a neurotransmitter and may play a 
role in cell growth and in the development of the nerv- 
ous system. SRIF has been reported to prevent natu- 
rally occuring motoneuron cell death in the embryonal 
spinal cord [‘7]. Interestingly, SSTRI mRNA and, to a 
lower extent, SSTRZ mRNA could be detected in the 
spinal cord (Fig. 1). Conceivably, the neurotrophic ac- 
tions of SRIF on these cells are mediated by SSTRl or 
2. In rodent epilepsy models, an ant~~onvulsant effect 
of somatostatin has been discussed [44]. The seizure 
activity caused by intrahippocampal injections of kainic 
or quinolinic acid, two excitatory amino acids acting on 
glutamate receptors, could be inhibited by local admin- 
istration of SRIF or its analogue SMS 201-995. The 
expression of the SMS 201-995 sensitive receptor sub- 
type SSTRZ in the hippocampus uggests that the anti- 
convulsant actions of SRIF may be mediated through 
SSTR2. 
SRIF receptors which have been shown to belong to 
the family of G-protein coupled receptors, act on vari- 
ous cellular effector systems such as adenylyl cyclases 
[14], ion channels f4] or phosphatases [45]. In order to 
characterize the cellular effector systems of the cloned 
SSTR subtypes, human SSTRl-4 were stably expressed 
in HEK 293 cells. Agonist binding to all four receptors 
inhibited the forskolin-induced CAMP formation in 
cells expressing SSTR1-4. The inhibition was pertussis 
toxin-sensitive indicating the coupling of these receptors 
to pertussis toxin-sensitive G-proteins. Rat SSTR2 and 
human and mouse SSTR3 have previously been de- 
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Fig. 4. Inhibition of forskohn-induced CAMP formation by agonist bmdmg to SRIF receptors expressed m HEK 293 cells. The results of typtcal 
expertments are shown as mean & S.E M. for duplicate or triplicate determinations c control (basal CAMP level), Fsk: forakolin, PTX: pertussis 
toxm. 
cribed to mediate the inhibition of adenylyl cyclase 
[19,23,46]. In the present study we demonstrated that 
hSSTR1 and the recently cloned hSSTR4 inhibit ade- 
nylyl cyclase activity. In contrast, Reisine and co-work- 
ers reported that human SSTRl, after expression in 
CHO and COS cells, and human SSTR2, after expres- 
sion in COS, CHO and HEK 293 cells, do not show this 
inhibitory effect on CAMP formation [36,37]. In agree- 
ment with this we did not find coupling of SSTRI to 
adenylyl cyclase after stable transfection in CHO cells 
(data not shown). The negative coupling of SSTR2 to 
adenylyl cyclase is further confirmed by the fact that 
SRIF receptors in AR4-2J cells can inhibit adenylyl 
cyclase via pertussis toxin-sensitive G-proteins [47]. 
This pancreatic acinar cell line predominantly expresses 
SSTR2 ([15]; Kaupmann et al., unpublished). In addi- 
tion, we observed negative coupling of the SSTR2 re- 
ceptors to adenylyl cyclase in Neuro2A cells, which 
express this receptor subtype selectively (data not 
shown). 
The cloning of a fifth SRIF receptor expressed in the 
pituitary has recently been published [23]. The DNA 
sequence, the binding properties, and second messenger 
coupling (inhibition of adenylyl cyclase) of this receptor 
are closely related to SSTR2. 
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